Abstract
3′-5′-cyclic adenosine monophosphate (cAMP) and phosphatidylinositol 3,4,5 trisphosphate (PIP3) are pleiotropic second messengers generated in response to activation of G protein-coupled receptors (GPCRs) by a wide array of hormones and neurotransmitters. Although these small molecules engage distinct and seemingly unrelated downstream signal transducers, a growing body of evidence points to a strict cooperation of cAMP and PIP3 cascades in the control of cardiomyocyte functions. Dynamic macromolecular complexes of cAMP and PIP3 molecular switches assemble into spatially and temporally restricted microdomains. Deciphering how these compartmentalized complexes form and affect the interactions between the two signaling systems is of crucial importance, since both pathways are severely deregulated in major cardiac diseases, such as heart failure. This chapter summarizes recently described mechanisms governing the bidirectional cross talk between cAMP and PIP3 signaling pathways in the pathophysiological control of cardiovascular function. In particular, we will describe how membrane-located PIP3 affects both initiation and termination of cAMP signaling as well as the negative feedback loop whereby the small and diffusible intracellular messenger, cAMP, influences PIP3 production.
References
Ahmad F, Lindh R, Tang Y, Weston M, Degerman E, Manganiello VC (2007) Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. Biochem J 404(2):257–268
Dbouk HA, Vadas O, Shymanets A, Burke JE, Salamon RS, Khalil BD, Barrett MO, Waldo GL, Surve C, Hsueh C, Perisic O, Harteneck C, Shepherd PR, Harden TK, Smrcka AV, Taussig R, Bresnick AR, Nurnberg B, Williams RL, Backer JM (2012) G protein-coupled receptor-mediated activation of p110beta by Gbetagamma is required for cellular transformation and invasiveness. Sci Signal 5(253):ra89
Fang R, Cui Q, Sun J, Duan X, Ma X, Wang W, Cheng B, Liu Y, Hou Y, Bai G (2015) PDK1/Akt/PDE4D axis identified as a target for asthma remedy synergistic with beta2 AR agonists by a natural agent arctigenin. Allergy 70(12):1622–1632
Feldman DS, Carnes CA, Abraham WT, Bristow MR (2005) Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2(9):475–483
Ghigo A, Li M (2015) Phosphoinositide 3-kinase: friend and foe in cardiovascular disease. Front Pharmacol 6:169
Ghigo A, Perino A, Mehel H, Zahradnikova A Jr, Morello F, Leroy J, Nikolaev VO, Damilano F, Cimino J, De Luca E, Richter W, Westenbroek R, Catterall WA, Zhang J, Yan C, Conti M, Gomez AM, Vandecasteele G, Hirsch E, Fischmeister R (2012) Phosphoinositide 3-kinase gamma protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation 126(17):2073–2083
Han SJ, Vaccari S, Nedachi T, Andersen CB, Kovacina KS, Roth RA, Conti M (2006) Protein kinase B/Akt phosphorylation of PDE3A and its role in mammalian oocyte maturation. EMBO J 25(24):5716–5725
Kitamura T, Kitamura Y, Kuroda S, Hino Y, Ando M, Kotani K, Konishi H, Matsuzaki H, Kikkawa U, Ogawa W, Kasuga M (1999) Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol 19(9):6286–6296
Laketa V, Zarbakhsh S, Traynor-Kaplan A, Macnamara A, Subramanian D, Putyrski M, Mueller R, Nadler A, Mentel M, Saez-Rodriguez J, Pepperkok R, Schultz C (2014) PIP(3) induces the recycling of receptor tyrosine kinases. Sci Signal 7(308):ra5
Madamanchi A (2007) Beta-adrenergic receptor signaling in cardiac function and heart failure. Mcgill J Med 10(2):99–104
Mika D, Leroy J, Vandecasteele G, Fischmeister R (2012) PDEs create local domains of cAMP signaling. J Mol Cell Cardiol 52(2):323–329
Naga Prasad SV, Barak LS, Rapacciuolo A, Caron MG, Rockman HA (2001) Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration. J Biol Chem 276(22):18953–18959
Naga Prasad SV, Jayatilleke A, Madamanchi A, Rockman HA (2005) Protein kinase activity of phosphoinositide 3-kinase regulates β-adrenergic receptor endocytosis. Nat Cell Biol. 7(8):785–796
Ndongson-Dongmo B, Heller R, Hoyer D, Brodhun M, Bauer M, Winning J, Hirsch E, Wetzker R, Schlattmann P, Bauer R (2015) Phosphoinositide 3-kinase gamma controls inflammation-induced myocardial depression via sequential cAMP and iNOS signalling. Cardiovasc Res 108(2):243–253
Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100(3):309–327
Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, Marengo S, Russo G, Azzolino O, Rybalkin SD, Silengo L, Altruda F, Wetzker R, Wymann MP, Lembo G, Hirsch E (2004) PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118(3):375–387
Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, Baillie GS, Damilano F, Dunlop AJ, Pawson C, Walser R, Levi R, Altruda F, Silengo L, Langeberg LK, Neubauer G, Heymans S, Lembo G, Wymann MP, Wetzker R, Houslay MD, Iaccarino G, Scott JD, Hirsch E (2011) Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110gamma. Mol Cell 42(1):84–95
Perino A, Ghigo A, Scott JD, Hirsch E (2012) Anchoring proteins as regulators of signaling pathways. Circ Res 111(4):482–492
Perrino C, Naga Prasad SV, Patel M, Wolf MJ, Rockman HA (2005) Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol 45(11):1862–1870
Perrino C, Schroder JN, Lima B, Villamizar N, Nienaber JJ, Milano CA, Naga Prasad SV (2007) Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure. Circulation 116(22):2571–2579
Reddy GR, Subramanian H, Birk A, Milde M, Nikolaev VO, Bunemann M (2015) Adenylyl cyclases 5 and 6 underlie PIP3-dependent regulation. FASEB J 29(8):3458–3471
Rockman HA, Koch WJ, Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415(6868):206–212
Salamon RS, Backer JM (2013) Phosphatidylinositol-3,4,5-trisphosphate: tool of choice for class I PI 3-kinases. BioEssays 35(7):602–611
Stuenaes JT, Bolling A, Ingvaldsen A, Rommundstad C, Sudar E, Lin FC, Lai YC, Jensen J (2010) Beta-adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKA. Br J Pharmacol 160(1):116–129
Torella D, Gasparri C, Ellison GM, Curcio A, Leone A, Vicinanza C, Galuppo V, Mendicino I, Sacco W, Aquila I, Surace FC, Luposella M, Stillo G, Agosti V, Cosentino C, Avvedimento EV, Indolfi C (2009) Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Am J Physiol Heart Circ Physiol 297(6):H2015–H2025
Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5):329–341
Vasudevan NT, Mohan ML, Gupta MK, Hussain AK, Naga Prasad SV (2011) Inhibition of protein phosphatase 2A activity by PI3Kgamma regulates beta-adrenergic receptor function. Mol Cell 41(6):636–648
Voigt P, Dorner MB, Schaefer M (2006) Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J Biol Chem 281(15):9977–9986
Wilson LS, Baillie GS, Pritchard LM, Umana B, Terrin A, Zaccolo M, Houslay MD, Maurice DH (2011) A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells. J Biol Chem 286(18):16285–16296
Zaccolo M (2009) cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br J Pharmacol 158(1):50–60
Compliance with Ethical Standards
Conflict of Interest Statement
Emilio Hirsch is cofounder of Kither Biotech, a company involved in the development of PI3K inhibitors. The other authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Ghigo, A., Pirozzi, F., Li, M., Hirsch, E. (2017). Chatting Second Messengers: PIP3 and cAMP. In: Nikolaev, V., Zaccolo, M. (eds) Microdomains in the Cardiovascular System. Cardiac and Vascular Biology, vol 3. Springer, Cham. https://doi.org/10.1007/978-3-319-54579-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-54579-0_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-54578-3
Online ISBN: 978-3-319-54579-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)